Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.
about
Dynamic regulation of serum aryl hydrocarbon receptor agonists in MSB Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMSAryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activityRole of TFH Cells in Promoting T Helper 17-Induced Neuroinflammation.
P2860
Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of spontaneous EAE b ...... ates, and disease progression.
@en
Treatment of spontaneous EAE b ...... ates, and disease progression.
@nl
type
label
Treatment of spontaneous EAE b ...... ates, and disease progression.
@en
Treatment of spontaneous EAE b ...... ates, and disease progression.
@nl
prefLabel
Treatment of spontaneous EAE b ...... ates, and disease progression.
@en
Treatment of spontaneous EAE b ...... ates, and disease progression.
@nl
P2093
P2860
P1476
Treatment of spontaneous EAE b ...... ates, and disease progression.
@en
P2093
Bruce A C Cree
Claude C A Bernard
Collin M Spencer
Kara L Pekarek
Michel Varrin-Doyer
Raymond A Sobel
Scott S Zamvil
Ulf Schulze-Topphoff
P2860
P356
10.1212/NXI.0000000000000272
P577
2016-09-21T00:00:00Z